SmartPeptide
CognitiveLimited human evidence

Selank

Synthetic analog of a fragment of human tuftsin, studied in Russia for anxiolytic and nootropic effects.

Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.

What the research shows

Russian clinical work suggests anxiolytic effects without sedation. Some EEG and BDNF-related findings.

What's still experimental

Independent western replication is limited. Mechanisms beyond GABAergic modulation are speculative.

Anecdotal / community reports

Reports of acute anxiety relief and improved focus are common online; effect sizes vary.

Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.

FDA approval status

Source: openFDA + DailyMed (NIH/NLM)
No FDA-approved drug label exists for “Selank”. This peptide is not currently approved by the FDA as a finished pharmaceutical product. Any commercial product claiming FDA approval should be treated with suspicion.

Doses studied in research

No established dose range

What published trials tested or FDA-approved labels specify. Reporting research facts — not a SmartPeptide recommendation.

No FDA-approved or established trial dose range for this peptide. Anecdotal ranges discussed in community forums exist but are not supported by published clinical trials, and SmartPeptide will not publish unverified doses.

This is the honest answer for peptides like BPC-157, IGF-1 LR3, MOTS-c, Epitalon and similar research compounds — robust human dose- ranging studies have not been published. Always work with a licensed clinician familiar with experimental peptides if you are considering any use.

FDA enforcement & recalls

Live · openFDA Drug Enforcement API
No FDA enforcement actions (recalls, market withdrawals, safety alerts) on record for “Selank”. This is the expected baseline for most peptides — the absence of recalls does NOT imply general safety, only that no formal FDA enforcement has been initiated against approved formulations.

Mechanism & targets

ChEMBL · UniProt · Open Targets
No mechanism data indexed in ChEMBL, UniProt, or Open Targets for “Selank”. This is common for unscheduled research peptides that haven't been studied in structured target-binding assays.

Live research

PubMed · ClinicalTrials.gov · Europe PMC · OpenAlex
PubMed papers
135
total
Human studies
0
MeSH: humans
Clinical trials
0
published
Active trials
0
10 total registered

Clinical trials (ClinicalTrials.gov)

All trials for "selank"

Europe PMC — 80 additional records

Includes EU/UK studies and PubMed Central full-text articles. Often surfaces research weeks before PubMed indexes it.

Research volume (OpenAlex topic graph)

Total works
334
all years
Last 5 years
142
recent activity
Open access
222
freely readable
OA share
66%
of all works

Human clinical evidence

Semantic Scholar · AI TLDRs · influence-ranked
Total indexed
174
all human + lab studies
Meta-analyses
0
highest evidence
Systematic reviews
0
quality-weighted
Clinical trials
0
published RCTs etc.

Most influential human studies

Ranking blends meta-analysis > systematic review > clinical trial weight with influential-citation count and recency. AI TLDRs by Semantic Scholar / Allen Institute for AI.

Research funding & verification

NIH RePORTER · CrossRef DOI registry

Publication landscape

CrossRef · DOI registry
Indexed works (CrossRef)
80
all DOIs registered
Retracted papers
0
no retractions on record
Top funders of indexed research
  • Russian Foundation for Basic Research2 works
  • Russian Science Foundation1 works
  • Russian Academy of Sciences programs: “Molecular and Cellular Biology”, “Basic Sciences for Medicine”, “Mechanisms of Integration of Molecular Systems in the Implementation of the Physiological Functions”1 works
  • Leading Scientific Schools1 works

Funder diversity is a credibility signal. Research concentrated in a single drug company's funding warrants more scrutiny than research funded across NIH, charities, and academic grants.

Preprints — cutting edge

bioRxiv · medRxiv · via Europe PMC
No preprints indexed yet for “selank”.

Known risks

Most data is from a single national research tradition; independent replication is limited.

Reported side effects

Reported as mild in available studies.

FDA adverse event reports (FAERS)

Updated quarterly by FDA
No reports found in the FDA Adverse Event Reporting System for “Selank”. This is normal for research-only peptides that are not marketed as FDA-approved drugs.

What requires medical supervision

Not FDA-approved. Discuss with a clinician — especially if you take other anxiolytics or antidepressants.

Questions for your clinician

  • What independent (non-Russian) human evidence exists?
  • Could this interact with SSRIs/SNRIs/benzodiazepines?

Editorially curated references

Discussions about Selank

Start a discussion
No discussions yet — be the first. Share what you've learned, what worked, what didn't, or a study you want translated into plain English.
See all Selank discussions Native, moderated, no buying or selling